120 related articles for article (PubMed ID: 6797060)
1. Infections with Pseudomonas aeruginosa in the compromised host.
Frøland SS
Scand J Infect Dis Suppl; 1981; 29():72-80. PubMed ID: 6797060
[TBL] [Abstract][Full Text] [Related]
2. Interference of Pseudomonas aeruginosa with immunospecific host defenses.
Petit JC; Daguet GL
Biomed Pharmacother; 1983; 37(9-10):422-8. PubMed ID: 6232960
[TBL] [Abstract][Full Text] [Related]
3. Synthetic peptide vaccine and antibody therapeutic development: prevention and treatment of Pseudomonas aeruginosa.
Cachia PJ; Hodges RS
Biopolymers; 2003; 71(2):141-68. PubMed ID: 12767116
[TBL] [Abstract][Full Text] [Related]
4. Modulation of macrophage function for defence of the lung against Pseudomonas aeruginosa.
Speert DP; Wong SY; Macdonald M; Sargeant R
Behring Inst Mitt; 1997 Feb; (98):274-82. PubMed ID: 9382751
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
Savoia D; Deplano C; Zucca M
Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
[TBL] [Abstract][Full Text] [Related]
6. Immune surveillance mechanisms of the skin against the stealth infection strategy of Pseudomonas aeruginosa-review.
Andonova M; Urumova V
Comp Immunol Microbiol Infect Dis; 2013 Sep; 36(5):433-48. PubMed ID: 23602428
[TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa infection and inflammation during contact lens wear: a review.
Willcox MD
Optom Vis Sci; 2007 Apr; 84(4):273-8. PubMed ID: 17435510
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa diversity in distinct paediatric patient groups.
Tramper-Stranders GA; van der Ent CK; Wolfs TF; Kimpen JL; Fleer A; Johansen U; Johansen HK; Høiby N
Clin Microbiol Infect; 2008 Oct; 14(10):935-41. PubMed ID: 18752596
[TBL] [Abstract][Full Text] [Related]
9. Vaccines and immunotherapy against Pseudomonas aeruginosa.
Döring G; Pier GB
Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
[TBL] [Abstract][Full Text] [Related]
10. The complement system and host defense against Pseudomonas endophthalmitis.
Aizuss DH; Mondino BJ; Sumner HL; Dethlefs BA
Invest Ophthalmol Vis Sci; 1985 Sep; 26(9):1262-6. PubMed ID: 4030253
[TBL] [Abstract][Full Text] [Related]
11. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
12. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
13. Role of innate and adaptive immunity in the pathogenesis of keratitis.
Hazlett LD
Ocul Immunol Inflamm; 2005; 13(2-3):133-8. PubMed ID: 16019672
[TBL] [Abstract][Full Text] [Related]
14. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense.
Steinhauser ML; Hogaboam CM; Kunkel SL; Lukacs NW; Strieter RM; Standiford TJ
J Immunol; 1999 Jan; 162(1):392-9. PubMed ID: 9886412
[TBL] [Abstract][Full Text] [Related]
15. Vaccine strategies against Pseudomonas aeruginosa infection in the lung.
Cripps AW; Dunkley ML; Clancy RL; Kyd J
Behring Inst Mitt; 1997 Feb; (98):262-8. PubMed ID: 9382749
[TBL] [Abstract][Full Text] [Related]
16. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung.
Nieuwenhuis EE; Matsumoto T; Exley M; Schleipman RA; Glickman J; Bailey DT; Corazza N; Colgan SP; Onderdonk AB; Blumberg RS
Nat Med; 2002 Jun; 8(6):588-93. PubMed ID: 12042809
[TBL] [Abstract][Full Text] [Related]
17. Corneal response to Pseudomonas aeruginosa infection.
Hazlett LD
Prog Retin Eye Res; 2004 Jan; 23(1):1-30. PubMed ID: 14766315
[TBL] [Abstract][Full Text] [Related]
18. [When bacteria communicate with each other: the significance of intercellular signals in acute Pseudomonas aeruginosa infections].
Van Delden C
Rev Med Suisse Romande; 2000 Jan; 120(1):7-13. PubMed ID: 10705785
[TBL] [Abstract][Full Text] [Related]
19. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
Pier GB
Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
[TBL] [Abstract][Full Text] [Related]
20. IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Pressler T
APMIS Suppl; 1996; 66():1-41. PubMed ID: 8972694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
